Advanced Filters
noise

psychosis Clinical Trials

A listing of psychosis medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.

Found 304 clinical trials

Virtual Agents-based Digital Interventions to Improve Health

KANOPEE is a free smartphone application providing screening, follow-up tools and autonomous digital interventions to lower psycho-social stress and its repercussions on sleep and behaviors in the general population. Additionally, KANOPEE permits an adaptation of the intervention to the subject (i.e., an adapted waiting period, frequency, and content), enabling to …

18 years of age All Phase N/A
V VIAL VERONIQUE

Understanding of Psychotic Disorders in Children With 22q11.2DS

The study PremiCeS22 will investigate the prodromal signals at the onset of psychotic disorders of children with 22q11.2 deletion syndrome

4 - 13 years of age All Phase N/A
A Axel Nordenskjöld, MD

A Randomized Controlled Trial With Rituximab for Psychotic Disorder in Adults

Immunological factors are assumed to be determinants for some psychiatric disorders, thus anti-inflammatory drugs may be helpful. However, studies on such treatments are scarce. An inflammatory modulating drug rituximab, cluster of differentiation antigen 20 antibodies (anti-CD20 antibodies), is a standard treatment for e.g. multiple sclerosis. The investigators aim to test …

18 - 55 years of age All Phase 2

Optimizing Engagement in Services for First-Episode Psychosis

This study will compare a 12-session behavioral activation (BA) intervention modified for first-episode psychosis (FEP) to usual community mental health care (i.e., treatment-as-usual; TAU) delivered over 6 months with a sample of Latinos with FEP and their families. Comparable family group sessions will also be delivered to participants in both …

15 - 35 years of age All Phase N/A
V Viviane AWASSI

Self-administered COgnitive Personalized Training in Early Psychosis

The overall objective of SCOPe is to improve early intervention in psychosis by providing an innovative eHealth tool that will enable personalized cognitive training, adapted to the individual's cognitive abilities. Cognitive remediation improves quality of life and functional outcome in patients with chronic psychosis. It would even be more efficacious …

16 - 35 years of age All Phase N/A

Family Peer Navigator for Early Psychosis for Black Families

Building upon formative research, this mixed methods study will be conducted in three phases to develop, refine, and pilot-test a multi-component Family Peer Navigator model designed to increase access to and initial engagement in coordinated specialty care for early psychosis among Black/African American families.

18 years of age All Phase N/A
R Rachel Jespersen, MSW

Telehealth Cognitive Behavioral Therapy for Youth at Risk for Psychosis

This study aims to evaluate the feasibility and effectiveness of telehealth interventions for individuals at clinical high risk for psychosis (CHR). Psychosis typically emerges during late adolescence or early adulthood, significantly impacting long-term functioning. While CHR programs have the potential to reduce illness severity, individuals often face barriers such as …

14 - 25 years of age All Phase N/A

Mechanisms of Response to Therapeutic Intervention in Clinical High Risk (CHR) for Psychosis

This study, "Psychobiological Follow-up Study of Transition from Prodrome to Early Psychosis", will be conducted in collaboration with the Shanghai Mental Health Center (SMHC) and several data processing sites in the United States. The current study builds on findings from the investigator's previous work that identified several biomarkers in participants …

15 - 35 years of age All Phase N/A
C Christophe LEMEY

Biomarkers Predictive of Thymic Evolution and Therapeutic Response at 2 Years in Patients With a First Psychotic Episode

Psychosis is a severe, common, and disabling psychological disorder. An epidemiological study conducted in England reported an incidence of 34 new cases per 100,000 person-years, with a peak between 16 and 19 years of age. Following a first psychotic episode, two clinical evolutions are possible: thymic psychosis (17%) and non …

15 - 30 years of age All Phase N/A
C Caroline Wagandt, BA

Clinical Trial Evaluating the Efficacy and Safety of AGB101 for Treatment of Parkinson's Disease Related Psychosis

This clinical trial will test whether AGB101 (low-dose levetiracetam, 220 mg, extended release tablet) can improve symptoms of psychosis in Parkinson's disease. Participants will be asked to complete up to 5 in-person study visits over approximately 20 weeks. Participants will receive both AGB101 and a placebo to take once a …

40 - 85 years of age All Phase 2

Simplify language using AI